Panacea Biotec Ltd. News and Updates

Keep track of all breaking news on Panacea Biotec Ltd. from all sources in a single place.

Load latest

Panacea Biotec Ltd.

02 Feb 2024

425.25

2.19%

Panacea Biotec shares trade flat after USFDA classifies Baddi facility as OAI

Moneycontrol

A meeting of the board of directors of the company is scheduled to be held on February 13 to consider and approve the unaudited financial results.

Panacea Biotec Ltd. has gained 204.99% in the last 1 Year

Panacea Biotec Ltd.

15 Dec 2023

425.25

2.19%

Panacea Biotec shares rise 5% on pentavalent vaccine launch in India

Moneycontrol

EasyFourPol is the world's first fully liquid wP-IPV Pentavalent vaccine, which protects children against five deadly diseases i.e. Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.

Number of FII/FPI investors increased from 11 to 22 in Mar 2025 qtr.

Panacea Biotec Ltd.

30 Oct 2023

425.25

2.19%

Panacea Biotec arm launches cancer drug in Canadian market; shares trade higher

Moneycontrol

Paclitaxel Protein-Bound Particles is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas.

Panacea Biotec Ltd. is trading above its 200 day SMA of 413.9

Panacea Biotec Ltd.

13 Oct 2023, 12:36PM

425.25

2.19%

Panacea Biotech slumps 5% after US FDA issues 9 observations on Baddi facility

Moneycontrol

The USFDA inspected the unit from October 03-12.

Panacea Biotec Ltd. is trading above its 200 day SMA of 413.9

Panacea Biotec share price falls over 3% after Baddi unit receives 9 observations from US FDA

livemint | 13 Oct 2023, 10:20AM

Panacea Biotec Ltd.

18 Sep 2023

425.25

2.19%

Panacea Biotec hits 52-week high on Serum Institute selling off 4 lakh shares

Moneycontrol

According to the data published by the NSE, the vaccine maker sold its shares in the company for the second time in the ongoing quarter after having offloaded 5 lakh shares in August at an average price of Rs 146.31.

Panacea Biotec Ltd. is trading above its 200 day SMA of 413.9

Panacea Biotec Ltd.

30 May 2023

425.25

2.19%

Panacea Biotec Consolidated March 2023 Net Sales at Rs 128.93 crore, down 8.38% Y-o-Y

Moneycontrol

Panacea Biotec Ltd. is trading above its 200 day SMA of 413.9

Panacea Biotec Ltd.

16 Mar 2023

425.25

2.19%

Johnson & Johnson's dengue antiviral drug shows positive results

Business Standard

Around November, the ICMR sought the drug regulator's nod for phase-3 trials of a vaccine candidate it developed with drugmakers SII and Panacea Biotec

Panacea Biotec Ltd. is trading below its 30 day SMA of 430.6

Panacea Biotec Ltd.

17 Feb 2023

425.25

2.19%

Panacea Biotec Consolidated December 2022 Net Sales at Rs 115.20 crore, down 26.1% Y-o-Y

Moneycontrol

Panacea Biotec Ltd. has gained 204.99% in the last 1 Year

Panacea Biotec Ltd.

15 Nov 2022

425.25

2.19%

Panacea Biotec Consolidated September 2022 Net Sales at Rs 105.12 crore, down 54.72% Y-o-Y

Moneycontrol

NULL

Panacea Biotec Ltd. is trading below its 30 day SMA of 430.6

Panacea Biotec Ltd.

08 Sep 2022

425.25

2.19%

USFDA asks Panacea Biotec to take corrective measures at Himachal unit

Business Standard

Panacea Biotec Ltd on Thursday said the US health regulator has asked for further corrective actions at the manufacturing unit of its wholly-owned arm at Baddi in Himachal Pradesh otherwise approval of any pending product applications from the facility may be withheld. The US Food and Drug Administration (USFDA) had inspected the Baddi unit of its subsidiary, Panacea Biotec Pharma Ltd (PBPL) from May 30 to June 8, 2022. Subsequently, the USFDA issued Form 483 with eight observations which are related to improvements in existing procedures and are addressable, Panacea Biotec said in a regulatory filing. According to the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company said it has "now received a communication from the USFDA indicating the inspection classification .

Number of FII/FPI investors increased from 11 to 22 in Mar 2025 qtr.

Is Panacea Biotec Ltd. worth buying?

219 Votes:

Buy 77.17%

Sell 13.24%

Hold 9.59%

26.92% Fall from 52W High

Panacea Biotec Ltd. News and Updates

Keep track of all breaking news on Panacea Biotec Ltd. from all sources in a single place.